Skip to main content
Erschienen in: Cellular Oncology 1/2016

01.02.2016 | Original Paper

miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway

verfasst von: Ismael Riquelme, Oscar Tapia, Pamela Leal, Alejandra Sandoval, Matthew G. Varga, Pablo Letelier, Kurt Buchegger, Carolina Bizama, Jaime A. Espinoza, Richard M. Peek, Juan Carlos Araya, Juan Carlos Roa

Erschienen in: Cellular Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Gastric cancer (GC) is a deadly malignancy worldwide. In the past, it has been shown that cellular signaling pathway alterations play a crucial role in the development of GC. In particular, deregulation of the PI3K/AKT/mTOR pathway seems to affect multiple GC functions including growth, proliferation, metabolism, motility and angiogenesis. Targeting alterations in this pathway by microRNAs (miRNAs) represents a potential therapeutic strategy, especially in inhibitor-resistant tumors. The objective of this study was to evaluate the expression of 3 pre-selected miRNAs, miR-101-2, miR-125b-2 and miR-451a, in a series of primary GC tissues and matched non-GC tissues and in several GC-derived cell lines, and to subsequently evaluate the functional role of these miRNAs.

Methods

Twenty-five primary GC samples, 25 matched non-GC samples and 3 GC-derived cell lines, i.e., AGS, MKN28 and MKN45, were included in this study. miRNA and target gene expression levels were assessed by quantitative RT-PCR and western blotting, respectively. Subsequently, cell viability, clone formation, cell death, migration and invasion assays were performed on AGS cells.

Results

miR-101-2, miR-125b-2 and miR-451a were found to be down-regulated in the primary GC tissues and the GC-derived cell lines tested. MiRNA mimic transfections significantly reduced cell viability and colony formation, increased cell death and reduced cell migration and invasion in AGS cells. We also found that exogenous expression of miR-101-2, miR-125b-2 and miR-451a decreased the expression of their putative targets MTOR, PIK3CB and TSC1, respectively.

Conclusions

Our expression analyses and in vitro functional assays suggest that miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in primary GCs as well as in GC-derived AGS cells.
Literatur
1.
Zurück zum Zitat A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011)CrossRefPubMed A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011)CrossRefPubMed
2.
Zurück zum Zitat A. Yousuf, M.Y. Bhat, A.A. Pandith, D. Afroze, N.P. Khan, K. Alam, P. Shah, M.A. Shah, S. Mudassar, A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, M.G.M.T. Gene, Silencing by promoter hypermethylation in gastric cancer in a high incidence area. Cell. Oncol. 37, 245–52 (2014)CrossRef A. Yousuf, M.Y. Bhat, A.A. Pandith, D. Afroze, N.P. Khan, K. Alam, P. Shah, M.A. Shah, S. Mudassar, A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, M.G.M.T. Gene, Silencing by promoter hypermethylation in gastric cancer in a high incidence area. Cell. Oncol. 37, 245–52 (2014)CrossRef
3.
Zurück zum Zitat V. Catalano, R. Labianca, G.D. Beretta, G. Gatta, F. de Braud, E. Van Cutsem, Gastric cancer. Crit. Rev. Oncol. Hematol. 71, 127–64 (2009)CrossRefPubMed V. Catalano, R. Labianca, G.D. Beretta, G. Gatta, F. de Braud, E. Van Cutsem, Gastric cancer. Crit. Rev. Oncol. Hematol. 71, 127–64 (2009)CrossRefPubMed
5.
Zurück zum Zitat M. Labots, T.E. Buffart, J.C. Haan, N.C.T. van Grieken, M. Tijssen, C.J.H. van de Velde, H.I. Grabsch, B. Ylstra, B. Carvalho, R.J.A. Fijneman, H.M.W. Verheul, G.A. Meijer, High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. Cell. Oncol. 37, 41–52 (2014)CrossRef M. Labots, T.E. Buffart, J.C. Haan, N.C.T. van Grieken, M. Tijssen, C.J.H. van de Velde, H.I. Grabsch, B. Ylstra, B. Carvalho, R.J.A. Fijneman, H.M.W. Verheul, G.A. Meijer, High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. Cell. Oncol. 37, 41–52 (2014)CrossRef
6.
Zurück zum Zitat B.J. Dicken, D.L. Bigam, C. Cass, J.R. Mackey, A.A. Joy, S.M. Hamilton, Gastric adenocarcinoma: review and considerations for future directions. Ann. Surg. 241, 27–39 (2005)PubMedCentralPubMed B.J. Dicken, D.L. Bigam, C. Cass, J.R. Mackey, A.A. Joy, S.M. Hamilton, Gastric adenocarcinoma: review and considerations for future directions. Ann. Surg. 241, 27–39 (2005)PubMedCentralPubMed
7.
Zurück zum Zitat S.-E. Al-Batran, M. Ducreux, A. Ohtsu, mTOR as a therapeutic target in patients with gastric cancer. Int. J. Cancer 130, 491–6 (2012)CrossRefPubMed S.-E. Al-Batran, M. Ducreux, A. Ohtsu, mTOR as a therapeutic target in patients with gastric cancer. Int. J. Cancer 130, 491–6 (2012)CrossRefPubMed
8.
Zurück zum Zitat O. Tapia, I. Riquelme, P. Leal, A. Sandoval, S. Aedo, H. Weber, P. Letelier, E. Bellolio, M. Villaseca, P. Garcia, J.C. Roa, The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 465, 25–33 (2014)CrossRefPubMed O. Tapia, I. Riquelme, P. Leal, A. Sandoval, S. Aedo, H. Weber, P. Letelier, E. Bellolio, M. Villaseca, P. Garcia, J.C. Roa, The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 465, 25–33 (2014)CrossRefPubMed
9.
Zurück zum Zitat The Cancer Genome Atlas Research Network, Comprehensive Molecular Characterization of Gastric Adenocarcinoma. Nature. 513, 202–9 (2014) The Cancer Genome Atlas Research Network, Comprehensive Molecular Characterization of Gastric Adenocarcinoma. Nature. 513, 202–9 (2014)
10.
Zurück zum Zitat E. Caron, S. Ghosh, Y. Matsuoka, D. Ashton-Beaucage, M. Therrien, S. Lemieux, C. Perreault, P.P. Roux, H. Kitano, A comprehensive map of the mTOR signaling network. Mol. Syst. Biol. 6, 453 (2010)PubMedCentralCrossRefPubMed E. Caron, S. Ghosh, Y. Matsuoka, D. Ashton-Beaucage, M. Therrien, S. Lemieux, C. Perreault, P.P. Roux, H. Kitano, A comprehensive map of the mTOR signaling network. Mol. Syst. Biol. 6, 453 (2010)PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat D. Morgensztern, H.L. McLeod, PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16, 797–803 (2005)CrossRefPubMed D. Morgensztern, H.L. McLeod, PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16, 797–803 (2005)CrossRefPubMed
12.
Zurück zum Zitat D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–97 (2004)CrossRefPubMed D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–97 (2004)CrossRefPubMed
13.
Zurück zum Zitat Y. Wang, M. Li, W. Zang, Y. Ma, N. Wang, P. Li, T. Wang, G. Zhao, MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell. Oncol. 36, 385–94 (2013)CrossRef Y. Wang, M. Li, W. Zang, Y. Ma, N. Wang, P. Li, T. Wang, G. Zhao, MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell. Oncol. 36, 385–94 (2013)CrossRef
15.
Zurück zum Zitat A. Esquela-Kerscher, F.J. Slack, Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259–69 (2006)CrossRefPubMed A. Esquela-Kerscher, F.J. Slack, Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259–69 (2006)CrossRefPubMed
16.
Zurück zum Zitat R. Nagadia, P. Pandit, W.B. Coman, J. Cooper-White, C. Punyadeera, miRNAs in head and neck cancer revisited. Cell. Oncol. 36, 1–7 (2013)CrossRef R. Nagadia, P. Pandit, W.B. Coman, J. Cooper-White, C. Punyadeera, miRNAs in head and neck cancer revisited. Cell. Oncol. 36, 1–7 (2013)CrossRef
17.
18.
Zurück zum Zitat K.N. Ivey, D. Srivastava, MicroRNAs as regulators of differentiation and cell fate decisions. Cell Stem Cell 7, 36–41 (2010)CrossRefPubMed K.N. Ivey, D. Srivastava, MicroRNAs as regulators of differentiation and cell fate decisions. Cell Stem Cell 7, 36–41 (2010)CrossRefPubMed
19.
Zurück zum Zitat R. Garzon, M. Fabbri, A. Cimmino, G.A. Calin, C.M. Croce, MicroRNA expression and function in cancer. Trends Mol. Med. 12, 580–7 (2006)CrossRefPubMed R. Garzon, M. Fabbri, A. Cimmino, G.A. Calin, C.M. Croce, MicroRNA expression and function in cancer. Trends Mol. Med. 12, 580–7 (2006)CrossRefPubMed
21.
Zurück zum Zitat M. Fabbri, miRNAs as molecular biomarkers of cancer. Expert Rev. Mol. Diagn. 10, 435–44 (2010)CrossRefPubMed M. Fabbri, miRNAs as molecular biomarkers of cancer. Expert Rev. Mol. Diagn. 10, 435–44 (2010)CrossRefPubMed
22.
Zurück zum Zitat E. Chan, D.E. Prado, J.B. Weidhaas, Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends Mol. Med. 17, 235–43 (2011)PubMedCentralCrossRefPubMed E. Chan, D.E. Prado, J.B. Weidhaas, Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends Mol. Med. 17, 235–43 (2011)PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat A. Strillacci, C. Griffoni, P. Sansone, P. Paterini, G. Piazzi, G. Lazzarini, E. Spisni, M.A. Pantaleo, G. Biasco, V. Tomasi, MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp. Cell Res. 315, 1439–47 (2009)CrossRefPubMed A. Strillacci, C. Griffoni, P. Sansone, P. Paterini, G. Piazzi, G. Lazzarini, E. Spisni, M.A. Pantaleo, G. Biasco, V. Tomasi, MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp. Cell Res. 315, 1439–47 (2009)CrossRefPubMed
24.
Zurück zum Zitat R.B. Batchu, O. Gruzdyn, A.M. Qazi, D. Bouwman, S.A. Gruber, D.W. Weaver, MicroRNA-101 (miR-101) enhances chemosensitivity of pancreatic ductal adenocarcinoma (PDAC) cells by inhibition of MTOR signaling Via PRAS40. J. Surg. Res. 172, 233 (2012)CrossRef R.B. Batchu, O. Gruzdyn, A.M. Qazi, D. Bouwman, S.A. Gruber, D.W. Weaver, MicroRNA-101 (miR-101) enhances chemosensitivity of pancreatic ductal adenocarcinoma (PDAC) cells by inhibition of MTOR signaling Via PRAS40. J. Surg. Res. 172, 233 (2012)CrossRef
25.
Zurück zum Zitat J. Buechner, E. Tømte, B.H. Haug, J.R. Henriksen, C. Løkke, T. Flægstad, C. Einvik, Tumour-suppressor microRNAs Let-7 and Mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br. J. Cancer 105, 296–303 (2011)PubMedCentralCrossRefPubMed J. Buechner, E. Tømte, B.H. Haug, J.R. Henriksen, C. Løkke, T. Flægstad, C. Einvik, Tumour-suppressor microRNAs Let-7 and Mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br. J. Cancer 105, 296–303 (2011)PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat C.-W. Chiang, Y. Huang, K.-W. Leong, L.-C. Chen, H.-C. Chen, S.-J. Chen, C.-K. Chou, PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells. J. Biomed. Sci. 17, 35 (2010)PubMedCentralCrossRefPubMed C.-W. Chiang, Y. Huang, K.-W. Leong, L.-C. Chen, H.-C. Chen, S.-J. Chen, C.-K. Chou, PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells. J. Biomed. Sci. 17, 35 (2010)PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat L. Liang, C.-M. Wong, Q. Ying, D.N.-Y. Fan, S. Huang, J. Ding, J. Yao, M. Yan, J. Li, M. Yao, I.O.-L. Ng, X. He, MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology 52, 1731–40 (2010)CrossRefPubMed L. Liang, C.-M. Wong, Q. Ying, D.N.-Y. Fan, S. Huang, J. Ding, J. Yao, M. Yan, J. Li, M. Yao, I.O.-L. Ng, X. He, MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology 52, 1731–40 (2010)CrossRefPubMed
28.
Zurück zum Zitat L. Liu, H. Li, J. Li, H. Zhong, H. Zhang, J. Chen, T. Xiao, miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem. Biophys. Res. Commun. 416, 31–8 (2011)CrossRefPubMed L. Liu, H. Li, J. Li, H. Zhong, H. Zhang, J. Chen, T. Xiao, miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem. Biophys. Res. Commun. 416, 31–8 (2011)CrossRefPubMed
29.
Zurück zum Zitat G.K. Scott, A. Goga, D. Bhaumik, C.E. Berger, C.S. Sullivan, C.C. Benz, Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282, 1479–86 (2007)CrossRefPubMed G.K. Scott, A. Goga, D. Bhaumik, C.E. Berger, C.S. Sullivan, C.C. Benz, Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282, 1479–86 (2007)CrossRefPubMed
30.
Zurück zum Zitat E. Bandres, N. Bitarte, F. Arias, J. Agorreta, P. Fortes, X. Agirre, R. Zarate, J.A. Diaz-Gonzalez, N. Ramirez, J.J. Sola, P. Jimenez, J. Rodriguez, J. Garcia-Foncillas, microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin. Cancer Res. 15, 2281–90 (2009)CrossRefPubMed E. Bandres, N. Bitarte, F. Arias, J. Agorreta, P. Fortes, X. Agirre, R. Zarate, J.A. Diaz-Gonzalez, N. Ramirez, J.J. Sola, P. Jimenez, J. Rodriguez, J. Garcia-Foncillas, microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin. Cancer Res. 15, 2281–90 (2009)CrossRefPubMed
31.
Zurück zum Zitat Y. Nan, L. Han, A. Zhang, G. Wang, Z. Jia, Y. Yang, X. Yue, P. Pu, Y. Zhong, C. Kang, MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 1359, 14–21 (2010)CrossRefPubMed Y. Nan, L. Han, A. Zhang, G. Wang, Z. Jia, Y. Yang, X. Yue, P. Pu, Y. Zhong, C. Kang, MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 1359, 14–21 (2010)CrossRefPubMed
32.
Zurück zum Zitat J. Godlewski, M.O. Nowicki, A. Bronisz, G. Nuovo, J. Palatini, M. De Lay, J. Van Brocklyn, M.C. Ostrowski, E.A. Chiocca, S.E. Lawler, MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 37, 620–32 (2010)PubMedCentralCrossRefPubMed J. Godlewski, M.O. Nowicki, A. Bronisz, G. Nuovo, J. Palatini, M. De Lay, J. Van Brocklyn, M.C. Ostrowski, E.A. Chiocca, S.E. Lawler, MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 37, 620–32 (2010)PubMedCentralCrossRefPubMed
33.
Zurück zum Zitat H. Zhou, J.-M. Guo, Y.-R. Lou, X.-J. Zhang, F.-D. Zhong, Z. Jiang, J. Cheng, B.-X. Xiao, Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J. Mol. Med. (Berl.) 88, 709–17 (2010)CrossRef H. Zhou, J.-M. Guo, Y.-R. Lou, X.-J. Zhang, F.-D. Zhong, Z. Jiang, J. Cheng, B.-X. Xiao, Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J. Mol. Med. (Berl.) 88, 709–17 (2010)CrossRef
34.
Zurück zum Zitat H.-J. Wang, H.-J. Ruan, X.-J. He, Y.-Y. Ma, X.-T. Jiang, Y.-J. Xia, Z.-Y. Ye, H.-Q. Tao, MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur. J. Cancer 46, 2295–2303 (2010)CrossRefPubMed H.-J. Wang, H.-J. Ruan, X.-J. He, Y.-Y. Ma, X.-T. Jiang, Y.-J. Xia, Z.-Y. Ye, H.-Q. Tao, MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur. J. Cancer 46, 2295–2303 (2010)CrossRefPubMed
35.
Zurück zum Zitat Z.-X. Yang, C.-Y. Lu, Y.-L. Yang, K.-F. Dou, K.-S. Tao, MicroRNA-125b expression in gastric adenocarcinoma and its effect on the proliferation of gastric cancer cells. Mol. Med. Rep. 7, 229–232 (2013)PubMed Z.-X. Yang, C.-Y. Lu, Y.-L. Yang, K.-F. Dou, K.-S. Tao, MicroRNA-125b expression in gastric adenocarcinoma and its effect on the proliferation of gastric cancer cells. Mol. Med. Rep. 7, 229–232 (2013)PubMed
36.
Zurück zum Zitat Y. Cheng, L. Chen, X. Cao, S. Ha, X. Xia, Expression profiling and functional analysis of hsa-miR-125b and its target genes in drug-resistant cell line of human gastric cancer. Hereditas 36, 119–128 (2014)PubMed Y. Cheng, L. Chen, X. Cao, S. Ha, X. Xia, Expression profiling and functional analysis of hsa-miR-125b and its target genes in drug-resistant cell line of human gastric cancer. Hereditas 36, 119–128 (2014)PubMed
38.
Zurück zum Zitat I. Beuvink, A. Boulay, S. Fumagalli, F. Zilbermann, S. Ruetz, T. O’Reilly, F. Natt, J. Hall, H.A. Lane, G. Thomas, The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747–59 (2005)CrossRefPubMed I. Beuvink, A. Boulay, S. Fumagalli, F. Zilbermann, S. Ruetz, T. O’Reilly, F. Natt, J. Hall, H.A. Lane, G. Thomas, The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747–59 (2005)CrossRefPubMed
39.
40.
Zurück zum Zitat M.F. Crouch, Regulation of thrombin-induced stress fibre formation in swiss 3T3 cells by the 70-kDa S6 kinase. Biochem. Biophys. Res. Commun. 233, 193–9 (1997)CrossRefPubMed M.F. Crouch, Regulation of thrombin-induced stress fibre formation in swiss 3T3 cells by the 70-kDa S6 kinase. Biochem. Biophys. Res. Commun. 233, 193–9 (1997)CrossRefPubMed
41.
Zurück zum Zitat L.A. Berven, F.S. Willard, M.F. Crouch, Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp. Cell Res. 296, 183–95 (2004)CrossRefPubMed L.A. Berven, F.S. Willard, M.F. Crouch, Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp. Cell Res. 296, 183–95 (2004)CrossRefPubMed
42.
Zurück zum Zitat K. Sakakibara, B. Liu, S. Hollenbeck, K.C. Kent, Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am. J. Physiol. Heart Circ. Physiol. 288, H2861–H2868 (2005)CrossRefPubMed K. Sakakibara, B. Liu, S. Hollenbeck, K.C. Kent, Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am. J. Physiol. Heart Circ. Physiol. 288, H2861–H2868 (2005)CrossRefPubMed
43.
Zurück zum Zitat H.Y. Zhou, A.S.T. Wong, Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 147, 2557–66 (2006)CrossRefPubMed H.Y. Zhou, A.S.T. Wong, Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 147, 2557–66 (2006)CrossRefPubMed
44.
Zurück zum Zitat S.A. Lang, A. Gaumann, G.E. Koehl, U. Seidel, F. Bataille, D. Klein, L.M. Ellis, U. Bolder, F. Hofstaedter, H.-J. Schlitt, E.K. Geissler, O. Stoeltzing, Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int. J. Cancer 120, 1803–10 (2007)CrossRefPubMed S.A. Lang, A. Gaumann, G.E. Koehl, U. Seidel, F. Bataille, D. Klein, L.M. Ellis, U. Bolder, F. Hofstaedter, H.-J. Schlitt, E.K. Geissler, O. Stoeltzing, Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int. J. Cancer 120, 1803–10 (2007)CrossRefPubMed
45.
Zurück zum Zitat A. Akinleye, P. Avvaru, M. Furqan, Y. Song, D. Liu, Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J. Hematol. Oncol. 6, 88 (2013)PubMedCentralCrossRefPubMed A. Akinleye, P. Avvaru, M. Furqan, Y. Song, D. Liu, Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J. Hematol. Oncol. 6, 88 (2013)PubMedCentralCrossRefPubMed
46.
Zurück zum Zitat W. Li, L. Xie, X. He, J. Li, K. Tu, L. Wei, J. Wu, Y. Guo, X. Ma, P. Zhang, Z. Pan, X. Hu, Y. Zhao, H. Xie, G. Jiang, T. Chen, J. Wang, S. Zheng, J. Cheng, D. Wan, S. Yang, Y. Li, J. Gu, Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer 123, 1616–22 (2008)CrossRefPubMed W. Li, L. Xie, X. He, J. Li, K. Tu, L. Wei, J. Wu, Y. Guo, X. Ma, P. Zhang, Z. Pan, X. Hu, Y. Zhao, H. Xie, G. Jiang, T. Chen, J. Wang, S. Zheng, J. Cheng, D. Wan, S. Yang, Y. Li, J. Gu, Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer 123, 1616–22 (2008)CrossRefPubMed
47.
Zurück zum Zitat E.J. Ezratty, C. Bertaux, E.E. Marcantonio, G.G. Gundersen, Clathrin mediates integrin endocytosis for focal adhesion disassembly in migrating cells. J. Cell Biol. 187, 733–47 (2009)PubMedCentralCrossRefPubMed E.J. Ezratty, C. Bertaux, E.E. Marcantonio, G.G. Gundersen, Clathrin mediates integrin endocytosis for focal adhesion disassembly in migrating cells. J. Cell Biol. 187, 733–47 (2009)PubMedCentralCrossRefPubMed
48.
50.
Zurück zum Zitat D. Kim, S. Kim, H. Koh, S.O. Yoon, A.S. Chung, K.S. Cho, J. Chung, Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 15, 1953–62 (2001)CrossRefPubMed D. Kim, S. Kim, H. Koh, S.O. Yoon, A.S. Chung, K.S. Cho, J. Chung, Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 15, 1953–62 (2001)CrossRefPubMed
51.
52.
Zurück zum Zitat B. Brenner, M.B. Hoshen, O. Purim, M. Ben David, K. Ashkenazi, G. Marshak, Y. Kundel, R. Brenner, S. Morgenstern, M. Halpern, N. Rosenfeld, A. Chajut, Y. Niv, M. Kushnir, MicroRNAs as a potential prognostic factor in gastric cancer. World J. Gastroenterol. 17, 3976–85 (2011)PubMedCentralCrossRefPubMed B. Brenner, M.B. Hoshen, O. Purim, M. Ben David, K. Ashkenazi, G. Marshak, Y. Kundel, R. Brenner, S. Morgenstern, M. Halpern, N. Rosenfeld, A. Chajut, Y. Niv, M. Kushnir, MicroRNAs as a potential prognostic factor in gastric cancer. World J. Gastroenterol. 17, 3976–85 (2011)PubMedCentralCrossRefPubMed
Metadaten
Titel
miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway
verfasst von
Ismael Riquelme
Oscar Tapia
Pamela Leal
Alejandra Sandoval
Matthew G. Varga
Pablo Letelier
Kurt Buchegger
Carolina Bizama
Jaime A. Espinoza
Richard M. Peek
Juan Carlos Araya
Juan Carlos Roa
Publikationsdatum
01.02.2016
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 1/2016
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-015-0247-3

Weitere Artikel der Ausgabe 1/2016

Cellular Oncology 1/2016 Zur Ausgabe

Neu im Fachgebiet Pathologie